---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-25-000034"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:21:43.892957+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Summit Therapeutics reports preliminary cash ≥$410M as of Dec 31, 2024

## Summary
- Preliminary unaudited cash, cash equivalents, and short-term investments at least $410M.
- Includes repayment of $31.8M related party loan (principal + interest) previously outstanding.
- Amount is preliminary and subject to completion of year-end financial closing procedures.
- Company presenting at J.P. Morgan Healthcare Conference on January 13, 2025.

## SEC filing metadata
- accession: 0001599298-25-000034
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000034/0001599298-25-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000034/smmt-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-25-000034
- JSON: https://secwatch.observer/filing/0001599298-25-000034.json
- Plain text: https://secwatch.observer/filing/0001599298-25-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.